Compare Crispr Therapeutics AG (CRSP) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Atlassian Corporation PLC — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Atlassian Corporation PLC trades at $94.47 (market cap $22.62B). The key difference: Atlassian Corporation PLC is far larger — about 4.6× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | TEAM | |
|---|---|---|
Market Cap | $4.97B | $22.62B |
Sector | Health | Technology |
52-Week High | $76.78 | $203.00 |
52-Week Low | $44.34 | $57.15 |
Enterprise Value | $3.32B | $22.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Atlassian (TEAM) trades at $96.11, up 8.16% today, with strong technical momentum and bullish analyst sentiment. The stock shows accelerating revenue growth (32% YoY in Q3 FY26 per Zacks Investment Research, 2026-06-24) and improving margins, though it remains unprofitable. Recent earnings beats and cloud business expansion support positive outlook, while high valuation multiples and competitive pressures present risks.
Outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent net losses and elevated valuation. Wall Street consensus price target of $115.69 suggests 20% upside, though execution on profitability is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
